CoChat
Sign Up
Cited by 216Pancreatic function and diabetesPluripotent Stem Cells ResearchDiabetes and associated disorders

Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

Open access
Hogrebe, Nathaniel J., Ishahak, Matthew, Millman, Jeffrey R.·2023·Cell Stem Cell
DOI 10.1016/j.stem.2023.04.002PMC PMC10167558
Open this paper in CoChat — free accountOpen PDF

Abstract

The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

AI snapshot

Written from the paper’s full text.

TL;DR

This review summarizes advances in stem cell-derived islet (SC-islet) replacement therapy for type 1 diabetes, covering differentiation protocols, single-cell characterization, immune protection, and clinical translation. It argues SC-islets can improve glycemic control but still face functional immaturity, off-target cells, immune rejection, post-transplant stress, and manufacturing/safety hurdles.

Key findings

  • Clinical islet transplantation established feasibility: the Edmonton Protocol led to insulin independence in all seven patients at 1 year, though all but one required supplemental insulin by 10 years; later 5-year insulin independence rates reached 50–80%, and immediate graft loss was reduced from ≥50% to closer to 25%.
  • SC-islet clinical trials show promise but limitations: ViaCyte’s PEC-Direct produced glucose-responsive C-peptide 6–9 months post-transplant, but levels were too low for measurable clinical benefit; Vertex’s VX-880 preliminary press-release results improved glycemic control in two T1D patients, with slower effects than in rodents.
  • Single-cell studies reveal heterogeneity: scRNA-seq of 40,444 and 87,769 cells identified off-target SC-EC cells (TPH1/LMX1A, serotonin) sharing a NEUROG3+ progenitor with SC-β cells; multiomic analyses found >600 genes, ~350 promoter regions, and ~250 transcription factor binding motifs increased after 6 months in vivo.
  • Manufacturing/dose challenges remain: 2–5 × 10^6 SC-islet cells reverse hyperglycemia in mice, but humans may need ~10^9 cells per patient, so 1,000 patients require ~10^12 cells; the largest reported SC-islet differentiation was in 500 mL spinner flasks. Encapsulation with triazole–thiomorpholine dioxide alginate restored glycemic control in mice for at least 174 days without fibrosis.

Methods

  • Narrative review; no primary experiments or systematic search described.
  • Synthesizes preclinical rodent and non-human primate studies, human clinical trials (ViaCyte NCT02239354/NCT03163511; Vertex NCT04786262), and single-cell RNA-seq/ATAC-seq/multiomic studies.
  • Main analysis is qualitative synthesis of advances and challenges in SC-islet generation, immune protection, transplantation, scale-up, and safety.

Limitations

  • Stated: current SC-β cells remain less functional than primary human islets, transcriptionally/chromatin immature, and differentiation produces off-target SC-EC cells; immune rejection/immunosuppression, immediate post-transplant cell loss, scale-up/cryopreservation, and long-term safety remain unresolved.
  • Evident: as a narrative review, it does not systematically assess evidence quality; some cited clinical findings are preliminary, from a press release, or preprints under peer review.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.stem.2023.04.002

Cites

188 of 188 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

230 of 317 cited sources checked · 143 supported · 1 flagged · accuracy not yet measured

  • Premisecitation

    In 2014-15, several groups published protocols for generating stem cell-derived β (SC-β) cells that secreted insulin in response to glucose stimulation.

    “In 2014-15, several groups published protocols for generating stem cell-derived β (SC-β) cells that secreted insulin in response to glucose stimulation.36–38”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [36] Pagliuca FW, Millman JR, Gu M, Segel M, Dervort A. Van, Ryu JH, Peterson QP, Greiner D, and Melton DA (2014). Generation of functional human pancreatic ß-Cells in vitro. Cell 159, 428– 439. 25303535 PMC4617632 source
    • cites [37] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O’Dwyer S, Quiskamp N, Mojibian M, Albrecht T, (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol 32, 1121– 1133. 25211370 source
    • cites [38] Russ HA, Parent AV, Ringler JJ, Hennings TG, Nair GG, Shveygert M, Guo T, Puri S, Haataja L, Cirulli V, (2015). Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J. 34, 1759– 1772. 25908839 PMC4516429 source
  • Premisecitation

    The Edmonton Protocol initial trial led to insulin independence of all seven patients 1 year after transplantation.

    “Their initial trial led to insulin independence of all seven patients 1 year after transplantation, vastly improving previous islet transplantation outcomes due to optimization of their immunosuppression regimen as well as benefiting from improvements in islet isolation techniques.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [15] Shapiro J, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV (2000). Islet transplantation in seven patients with T1D using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med 343, 230– 238. 10911004 source
    • cites [16] Bottino R, Knoll MF, Knoll CA, Bertera S, and Trucco MM (2018). The future of islet transplantation is now. Front. Med 5, 1– 13. PMC6053495 30057900 source
  • Premisecitation

    Observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells.

    “While the observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells, these clinical trials have demonstrated that facilitating host-derived vascularization into the graft promoted long-term endocrine cell survival and function in humans.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source

      The Discussion (page unavailable) says clinical improvements could not be clearly attributed to graft-derived C-peptide: outcomes did not differ between patients with higher and lower levels, and C-peptide secretion was likely not the major cause of improvement. But it does not establish that the levels were too low to produce any benefit; it suggests that some patients’ levels may be adequate for some clinical benefit. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608 source

      The Discussion’s ‘Limitations of the study’ section reports measurable C-peptide but no statistically significant clinical benefit in this pilot study. It says the lack of benefit is *most likely* due to insufficient engrafted β-cell mass; the claim states more definitively that the circulating C-peptide levels were too low to cause a benefit and extends the finding to multiple studies. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Premisecitation

    Upon graft removal, a majority of graft-derived cells immunostained for the general endocrine marker chromogranin A (CHGA).

    “Upon graft removal, a majority of these graft-derived cells immunostained for the general endocrine marker chromogranin A (CHGA).”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source

      The Results (page unavailable) report abundant synaptophysin-positive endocrine cell populations in explanted grafts. They do not report chromogranin A (CHGA) staining or establish that a majority of graft-derived cells stained for CHGA. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608 source
  • Premisecitation

    Transplanting cells from multiple genetic backgrounds per patient could exacerbate immune rejection and graft failure.

    “Not only are the number of pancreases available for islet isolation limited, but transplanting cells from multiple genetic backgrounds per patient could exacerbate immune rejection and graft failure.25,26”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [25] Campbell PM, Senior PA, Salam A, LaBranche K, Bigam DL, Kneteman NM, Imes S, Halpin A, Ryan EA, and Shapiro AMJ (2007). High risk of sensitization after failed islet transplantation. Am. J. Transplant 7, 2311– 2317. 17845564 source

      The Introduction (page unavailable) says that islets from multiple donors are often needed and that HLA mismatches may lead to antibodies. The Discussion (page unavailable) links multiple mismatches to broad sensitization, but says the role of these antibodies in islet graft failure is difficult to prove. The paper therefore supports the immune-risk concern, not a demonstrated link from multiple donors to rejection and graft failure. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [26] Rickels MR, Kearns J, Markmann E, Palanjian M, Markmann JF, Naji A, and Kamoun M (2006). HLA sensitization in islet transplantation. Clin. Transplant, 413– 420. PMC4562323 18365398
    • Rests on an assumption: The number of donor pancreases available for islet isolation is limited.
  • May combine two claims. 76
  • Classified as probably not a substantial claim. 16
  • The quote only partly states this claim. 3

  • May combine two claims.

    Premisecitation

    All but one of the Edmonton Protocol patients required supplemental insulin 10 years post-transplant, but all recipients retained some graft function that provided substantial benefits to glucose control and elimination of severe hypoglycemic events.

    “Although all but one of these patients required supplemental insulin 10 years post-transplant, all recipients retained some level of graft function that provided substantial benefits to glucose control and elimination of severe hypoglycemic events.17”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [17] Brennan DC, Kopetskie HA, and Sayre PH (2016). Long-term follow-up of the Edmonton Protocol of islet transplantation in the United States. Am. J. Transplant 16, 509– 517. 26433206 source

      Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Transplantation of pancreatic islets alone had limited success until the Edmonton Protocol in 2000 demonstrated that infusion of islets into the liver via the portal vein was sufficient to restore glucose homeostasis.

    “Transplantation of pancreatic islets alone to restore β cell mass, however, had limited success until the development of the Edmonton Protocol in 2000, which demonstrated that infusion of islets into the liver via the portal vein was sufficient to restore glucose homeostasis.15,16”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [15] Shapiro J, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV (2000). Islet transplantation in seven patients with T1D using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med 343, 230– 238. 10911004 source
    • cites [16] Bottino R, Knoll MF, Knoll CA, Bertera S, and Trucco MM (2018). The future of islet transplantation is now. Front. Med 5, 1– 13. PMC6053495 30057900 source

      “A new millennium begins” reports that the 2000 Edmonton Protocol achieved insulin independence in seven patients, a substantial improvement over earlier results. But “Islet transplantation in the twentieth century” reports insulin independence after intraportal transplantation before 2000, so the source does not support the implication that Edmonton first demonstrated that portal-vein islet infusion could restore glucose control. No page numbers are provided in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    While there were regions of C-peptide positive β-like cells, a majority of the endocrine cells stained for the α cell marker glucagon; ductal cells and rare acinar cells were also observed.

    “Interestingly, while there were regions of C-peptide positive β-like cells, a majority of these endocrine cells stained for the α cell marker glucagon. Ductal cells and rare acinar cells were also observed.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source

      The Results (page not provided) describe insulin-immunoreactive cells with a mature β-cell phenotype, an explanted endocrine population enriched in glucagon-positive cells, and scattered duct-like structures. They report few acinar cells in devices that were never implanted, but do not establish that acinar cells were rare in the explanted grafts or describe C-peptide-positive staining of β-like cells. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Subsequent transplantation studies showed improved patient outcomes, with islet transplantation approaching the success of whole pancreas transplantation without the corresponding surgical risk.

    “Subsequent transplantation studies continued to show improved patient outcomes, with islet transplantation approaching the success of whole pancreas transplantation without the corresponding surgical risk.18–23”
    Quote in the paperSubstantial claim3 of 6 sources checked
    • cites [18] Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, (2012). Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35, 1436– 1445. 22723582 PMC3379615 source
    • cites [19] Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, MacHuron F, Hubert T, (2019). Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: A prospective parallel-arm cohort study. Diabetes Care 42, 2042– 2049. 31615852 source
    • cites [20] Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, Anderson B, O’Gorman D, Kin T, Bigam D, (2022). Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol. 10, 519– 532. 35588757 source

      The Methods findings (page unavailable) report insulin independence and sustained improvements in glycaemic control after islet transplantation. They do not establish that its success approaches whole-pancreas transplantation or that it avoids the corresponding surgical risk; the study did not compare those procedures. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [21] Moassesfar S, Masharani U, Frassetto LA, Szot GL, Tavakol M, Stock PG, and Posselt AM (2016). A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am. J. Transplant 16, 518– 526. 26595767 PMC5549848 source
    • cites [22] Shapiro AMJ, and Verhoeff K (2022). A spectacular year for islet and stem cell transplantation. Nat. Rev. Endocrinol 10. 36539606

      Not checked in the free run.

    • cites [23] Verhoeff K, Marfil-Garza BA, and Shapiro AMJ (2021). Update on islet cell transplantation. Curr. Opin. Organ Transplant 26, 397– 404. 34148980 source

  • May combine two claims.

    Premisecitation

    The porous design promoted the growth of host-derived blood vessels inside the device, and this phenomenon was more prominent in regions containing the graft-derived cells.

    “As intended, the porous design promoted the growth of host-derived blood vessels inside the device, and this phenomenon was more prominent in regions containing the graft-derived cells.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source

      The Introduction describes portals designed to let capillaries enter the device, and the Results report blood vessels in explanted devices and endothelial staining adjacent to insulin-positive graft cells. The paper does not report that vascular growth was more prominent in regions containing graft-derived cells than elsewhere in the device. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Some endocrine cells were observed, but fibrosis around the capsule resulted in graft loss, and no insulin secretion from the device was detected.

    “While some endocrine cells were observed, fibrosis around the capsule resulted in graft loss, and no insulin secretion from the device was detected.33,34”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source
    • cites [34] Dolgin E. (2016). Encapsulating the problem. Nature 540, S60– 62. 27926697 source

      In “Bounding into the Clinic” (page not specified), the paper says pancreatic precursors in ViaCyte’s device grew into insulin-producing β-cells in many recipients, but often died after a few months because of a fibrotic reaction on the device exterior. It does not say that no insulin secretion from the device was detected. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Graft success increases when a high number of islets are transplanted, often resulting in the need for multiple donor pancreases.

    “In particular, graft success increases when a high number of islets are transplanted, often resulting in the need for multiple donor pancreases. 15,20,24”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [15] Shapiro J, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV (2000). Islet transplantation in seven patients with T1D using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med 343, 230– 238. 10911004 source
    • cites [20] Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, Anderson B, O’Gorman D, Kin T, Bigam D, (2022). Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol. 10, 519– 532. 35588757 source

      The Methods and Findings passages report graft survival and factors associated with sustained survival, but do not link success to the number of islets transplanted. Searches for islet mass, islet equivalents, and multiple donor pancreases found no passage establishing that relationship or the claimed need for multiple donors; a relevant study appears only in the References. (LLM, conf=0.72)

      Experimental — accuracy not yet measured
    • cites [24] Hering BJ, Ballou CM, Bellin MD, Payne EH, Kandeel F, Witkowski P, Alejandro R, Rickels MR, and Barton FB (2022). Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry. Diabetologia, 163– 173. 36201044 PMC10355148 source

      The Results (‘The common favourable factors’; page unavailable) associate at least 325,000 infused islet equivalents with more favourable outcomes in the studied recipients. The Introduction says 74% received at least two islet infusions, but does not establish that achieving a high islet dose often requires multiple donor pancreases; the observational association also does not establish causation. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The transplanted PEC-Encap product was well tolerated with few adverse effects, but the trial was halted due to insufficient functional product engraftment.

    “While the transplanted PEC-Encap product was well tolerated with few adverse effects, the trial was halted due to insufficient functional product engraftment.33”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source

      The Introduction (page unavailable) says the first 19 PEC-Encap recipients tolerated the product well with few complications. It also reports inconsistent cell survival and no evidence of insulin secretion, but does not say the trial was halted or give insufficient functional engraftment as the reason for halting it. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    An ongoing clinical trial was started in 2017 at seven sites to test the PEC-Direct device (NCT03163511), and the first round of results have recently been published.

    “An ongoing clinical trial was started in 2017 at seven sites to test this device (clinicaltrials.gov: NCT03163511), and the first round of results have recently been published.33,35”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [33] Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 28, 2047– 2061. 34861146 source
    • cites [35] Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, Wilensky J, Daniels M, Wang RM, Brandon EP, (2021). Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2, 100466. PMC8714853 35028608

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    SC-EC cells persisted after transplantation and exhibited increased expression of key gene markers of their identity, such as TPH1.

    “Interestingly, SC-EC cells also persisted after transplantation and exhibited increased expression of key gene markers of their identity, such as TPH1.”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 source

      The Results section, “Transcriptional Changes of EC Cells within Transplanted Grafts” (page unavailable), says SC-EC cells continue to exist after transplantation and lists several EC-cell genes that are upregulated. It says TPH1 protein is expressed after transplantation, but does not say TPH1 gene expression increased. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Transcriptional changes after transplantation appeared to occur temporally, as some genes (e.g., G6PC2) increased in expression shortly after transplantation, while others (e.g., MAFA) took several months to upregulate.

    “These transcriptional changes appeared to occur temporally, as some genes (e.g., G6PC2) increased in expression shortly after transplantation, while others (e.g., MAFA) took several months to upregulate.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 source

      The Results section reports that MAFA was sharply upregulated at six months postengraftment, supporting the claim that it took months. It says G6PC2 increased early in in vitro culture, not shortly after transplantation, although it also reports further upregulation following engraftment without specifying when that occurred. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 source

      The Results section (‘SC-β Cells Mature within Transplanted Grafts’; page unavailable) reports that both G6PC2 and MAFA increase after transplantation and with pseudotime. The Discussion says some maturation genes are expressed before MAFA in pseudotime, but does not identify G6PC2 as one of them. Pseudotime does not establish that G6PC2 rose shortly after transplantation or that MAFA took several months to rise. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Transplantation of SC-islets into mice improves their insulin secretion and glucose responsiveness, suggesting that SC-islet immaturity can be resolved.

    “Transplantation of SC-islets into mice improves their insulin secretion and glucose responsiveness, suggesting that SC-islet immaturity can be resolved.”
    Quote in the paperSubstantial claim5 of 6 sources checked
    • cites [36] Pagliuca FW, Millman JR, Gu M, Segel M, Dervort A. Van, Ryu JH, Peterson QP, Greiner D, and Melton DA (2014). Generation of functional human pancreatic ß-Cells in vitro. Cell 159, 428– 439. 25303535 PMC4617632 source

      The Results section, “Stem Cell-Derived β Cells Function in vivo After Transplantation” (page unavailable), reports human insulin secretion and a response to glucose within two weeks of transplantation. It does not show that transplantation improved either property relative to the cells before transplantation. The separate Results section on in vitro function reports that SC-β cells were already glucose-responsive, so the proposed resolution of their immaturity is not established here. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [37] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O’Dwyer S, Quiskamp N, Mojibian M, Albrecht T, (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol 32, 1121– 1133. 25211370 source
    • cites [41] Vegas AJ, Veiseh O, Gürtler M, Millman JR, Pagliuca FW, Bader AR, Doloff JC, Li J, Chen M, Olejnik K, (2016). Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med 22, 306– 311. 26808346 PMC4825868 source

      The Abstract reports human C-peptide secretion and glucose responsiveness after SC-β-cell transplantation into diabetic mice. But it describes the cells as mature and glucose-responsive before transplantation, and says they maintained their differentiation state afterward. It does not show that transplantation improved their function or resolved immaturity. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [42] Velazco-Cruz L, Song J, Maxwell KG, Goedegebuure MM, Augsornworawat P, Hogrebe NJ, and Millman JR (2019). Acquisition of dynamic function in human stem cell-derived β cells. Stem Cell Reports 12, 351– 365. 30661993 PMC6372986 source

      The Results section, “Transplantation of SC-β Cells into Glucose-Intolerant Mice” (page unavailable), reports glucose-responsive human insulin secretion after transplantation and improved glucose tolerance in recipient mice. But it does not show that transplantation improved the cells’ insulin secretion or glucose responsiveness relative to before transplantation. The Discussion instead attributes enhanced functional maturation to the six-stage differentiation strategy, so the claim that transplantation resolves immaturity is not supported. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 source

      The Results section, “SC-islets control the glycemia of mice in vivo” (page unavailable), reports glucose-regulated insulin secretion after engraftment, with higher C-peptide levels and faster glucose clearance for grafts matured longer in vitro. The Discussion (page unavailable) reports continued maturation after engraftment, but does not establish that transplantation itself improved insulin secretion or fully resolved SC-islet immaturity. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [44] Nair GG, Liu JS, Russ HA, Tran S, Saxton MS, Chen R, Juang C, Li M. Ian, Nguyen VQ, Giacometti S, (2019). Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells. Nat. Cell Biol 21, 263– 274. 30710150 PMC6746427 source

      The Results section, “Rapid onset of eBC functionality in vivo within days of transplantation” (page unavailable), reports glucose-responsive C-peptide secretion three days after transplantation and higher secretion eight months later. But the paper attributes the acquisition of mature glucose responsiveness chiefly to clustering in culture: the transplanted eBCs were already functional. It therefore does not establish that transplantation itself resolves SC-islet immaturity. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Previous analysis of scRNA-seq data alone had suggested that SC-β and SC-EC are distinct cell types that share a common progenitor lineage during in vitro differentiation of SC-islets.

    “Previous analysis of scRNA-seq data alone had suggested that SC-β and SC-EC are distinct cell types that share a common progenitor lineage during in vitro differentiation of SC-islets,”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [50] Weng C, Xi J, Li H, Cui J, Gu A, Lai S, Leskov K, Ke L, Jin F, and Li Y (2020). Single-cell lineage analysis reveals extensive multimodal transcriptional control during directed beta-cell differentiation. Nat. Metab 2, 1443– 1458. 33257854 PMC7744443 source

  • May combine two claims.

    Premisecitation

    SC-EC cells were identified, are absent from primary human islets, and resemble an endocrine cell type normally found in the intestines.

    “One of the most interesting findings from these scRNA-seq studies was the identification of SC-EC cells, which are absent from primary human islets and resemble an endocrine cell type normally found in the intestines.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source

      The SC-islets and SC-EC cells sections identify SC-EC cells and describe their resemblance to gut enterochromaffin cells. The Discussion says enterochromaffin cells have not previously been observed in studies of human islets, but also notes rare evidence suggesting resident pancreatic enterochromaffin cells; it does not establish that they are categorically absent from primary human islets. Page numbers are unavailable in our copy. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    1,150 endocrine-specific switch genes were identified, and it was inferred that 656 pairs of transcription factor and target gene interactions potentially influenced endocrine specification.

    “1,150 endocrine-specific switch genes were identified, and it was inferred that 656 pairs of transcription factor and target gene interactions potentially influenced endocrine specification.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [50] Weng C, Xi J, Li H, Cui J, Gu A, Lai S, Leskov K, Ke L, Jin F, and Li Y (2020). Single-cell lineage analysis reveals extensive multimodal transcriptional control during directed beta-cell differentiation. Nat. Metab 2, 1443– 1458. 33257854 PMC7744443 source

  • May combine two claims.

    Premisecitation

    SC-EC cells are characterized by the expression of enterochromaffin gene markers, such as TPH1 and LMX1A, as well as the secretion of serotonin rather than insulin.

    “These cells are characterized by the expression of enterochromaffin gene markers, such as TPH1 and LMX1A, as well as the secretion of serotonin rather than insulin.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source

      The “SC-EC cells” section reports TPH1 and LMX1A expression, serotonin content, and serotonin release from SC-islets; Extended Data Fig. 5 describes SC-EC cells as secreting serotonin. But the paper also reports low levels of insulin in SC-EC cells and does not establish that these cells secrete serotonin instead of insulin. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    With less optimized protocols or cell lines, there is potential to retain progenitor cells in the final islet clusters as well as produce other endodermal cell types, such as those of hepatic origin.

    “With less optimized protocols or cell lines, there is also the potential to retain progenitor cells in the final islet clusters as well as produce other endodermal cell types, such as those of hepatic origin.39,58”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [39] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat. Biotechnol 38, 460– 470. 32094658 PMC7274216 source

      The Introduction (page unavailable) says endodermal progenitors can produce non-pancreatic lineages, including hepatocytes. The Results section on cytoskeletal fate selection (page unavailable) also finds pancreatic progenitors and undefined endoderm under some differentiation conditions. These passages support the possibility of alternative cell fates, but they do not establish that less-optimized protocols or cell lines retain progenitors or produce hepatic cells in final islet clusters. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [58] Cuesta-Gomez N, Verhoeff K, Jasra IT, Pawlick R, Dadheech N, and Shapiro AMJ (2022). Characterization of stem-cell-derived islets during differentiation and after implantation. Cell Rep. 40, 111238. 36001981 source

      The Introduction (page unavailable) says stem-cell-derived islets can retain progenitors and describes non-pancreatic endodermal tissues arising from contaminating cells, particularly gastrointestinal and respiratory epithelia. It does not identify cells of hepatic origin, so that example is not supported by this source. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    SC-islets can be genetically engineered to both remove antigens that would signal them for destruction by the host immune system and add surface signaling molecules that induce immune tolerance.

    “Alternatively, the SC-islets themselves can be genetically engineered to both remove antigens that would signal them for destruction by the host immune system as well as add surface signaling molecules that induce immune tolerance.54,55”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [54] Gerace D, Zhou Q, Kenty JH, Boulanger KR, Li H, Melton DA, Gerace D, Zhou Q, Kenty JH, Veres A, (2023). Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Reports Med. 4, 100879. PMC9873825 36599351 source

      The Results section, ‘Engineering immune-evasive SC-islet cells’ (page unavailable), describes SC-islets engineered to lack HLA class I antigens and express surface PD-L1. But those cells were rejected in the paper’s xenograft model; the localized tolerance reported in the Results and Discussion came from engineered secretion of cytokines, not from added surface signaling molecules. The claim therefore combines two approaches while overstating what the surface-molecule approach achieved. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [55] Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, and Hebrok M (2021). Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538. 34407395 PMC12416289 source

  • May combine two claims.

    Premisecitation

    This differentiation methodology takes approximately a month or more to complete, and functional maturation can continue for months once the cells are transplanted in vivo.

    “This differentiation methodology takes approximately a month or more to complete, and functional maturation can continue for months once the cells are transplanted in vivo.43,51”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [43] Balboa D, Barsby T, Lithovius V, Saarimäki-Vire J, Omar-Hmeadi M, Dyachok O, Montaser H, Lund PE, Yang M, Ibrahim H, (2022). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol 40, 1042– 1055. 35241836 PMC9287162 source
    • cites [51] Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067. 32846125 PMC7491368 source

      The Results (Retrieval and Identification of SC-Islet Cell Populations after Transplantation; page unavailable) report improved glucose regulation after four weeks, further reversal of diabetes at six months, and increasing glucose-stimulated human C-peptide secretion. This supports functional maturation over months after transplantation. The Methods (Stem cell-derived β Cell differentiation; page unavailable) describe a six-stage protocol and transplantation on days 13–16 of stage 6, but do not establish that the full differentiation takes a month or more. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Immunosuppressive drugs used for whole organ transplants can successfully retain graft viability but can have serious side-effects, including an increased risk of infection and cancer as well as less severe but uncomfortable symptoms.

    “While these drugs can successfully retain graft viability, they also can have serious side-effects, including an increased risk of infection and cancer as well as less severe but uncomfortable symptoms.”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites [79] Rickels MR, and Paul Robertson R (2019). Pancreatic islet transplantation in humans: Recent progress and future directions. Endocr. Rev 40, 631– 668. 30541144 PMC6424003 source
    • cites [80] Blau J, Abegg M, Flegel W, Zhao X, Harlan D, and Rother K (2015). Long-term immunosupression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transpl. 15, 2995– 3001. PMC5158099 26184712 source

      The Case Reports > Complications section describes immunosuppression-related mouth ulcers, a cellulitis episode requiring hospitalization and antibiotics, and declining renal function. The Discussion and Patient A report support preservation of islet graft function during immunosuppression, but the paper does not address increased cancer risk or establish an increased infection risk in whole-organ transplant recipients. Page numbers are unavailable in our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [81] Ryan E, Paty B, Senior P, and Shapiro J (2004). Risks and side effects of islet transplantation. Curr. Diab. Rep 4, 304– 309. 15265474 source

  • May combine two claims.

    Premisecitation

    The amount of islet mass that is lost immediately following transplantation has been reduced closer to 25%, and thus fewer islets have been needed to achieve insulin independence.

    “In particular, the amount of islet mass that is lost immediately following transplantation has been reduced closer to 25%, and thus fewer islets have been needed to achieve insulin independence.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [79] Rickels MR, and Paul Robertson R (2019). Pancreatic islet transplantation in humans: Recent progress and future directions. Endocr. Rev 40, 631– 668. 30541144 PMC6424003 source
    • cites [125] Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, (2013). Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes 62, 2890– 2897. 23630300 PMC3717864 source

      The Discussion reports improved functional islet mass with the CIT07 protocol and insulin independence achieved with fewer transplanted islets than under the historical Edmonton protocol. But the Abstract’s ∼25% figure refers to β-cell secretory capacity relative to normal in Edmonton-protocol recipients—not the percentage of islet mass lost immediately after transplantation. The paper does not quantify immediate loss under CIT07 as 25%. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    A PTFE macroencapsulation device that actively pumped fluid through a hollow fiber running through its center demonstrated enhanced nutrient exchange that promoted cell survival and allowed for a greater cell density to be successfully loaded into the device.

    “For example, a PTFE macroencapsulation device that actively pumped fluid through a hollow fiber running through its center demonstrated enhanced nutrient exchange that promoted cell survival and allowed for a greater cell density to be successfully loaded into the device.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [94] Yang K, O’Cearbhaill ED, Liu SS, Zhou A, Chitnis GD, Hamilos AE, Xu J, Verma MKS, Giraldo JA, Kudo Y, (2021). A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion. Proc. Natl. Acad. Sci 118, 1– 12. PMC8449352 34504013 source

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    hPSCs with CRISPR/Cas9 removal of HLA-A, B, and C and CIITA, and overexpression of PD-L1, HLA-G, and CD47, differentiated into endothelial cells or vascular smooth muscle cells and demonstrated improved survival in co-cultures with T-cells, NK cells, and macrophages.

    “These cells could be differentiated into endothelial cells or vascular smooth muscle cells and demonstrated improved survival in co-cultures with T-cells, NK cells, and macrophages.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [119] Han X, Wang M, Duan S, Franco PJ, Kenty JHR, Hedrick P, Xia Y, Allen A, Ferreira LMR, Strominger JL, (2019). Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A 116, 10441– 10446. 31040209 PMC6535035 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The UPR aims to restore protein homeostasis under mild stress conditions but will induce apoptosis if the trigger is more severe.

    “While this pathway aims to restore protein homeostasis under mild stress conditions, it will induce apoptosis if the trigger is more severe.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 source

  • May combine two claims.

    Premisecitation

    Decreasing the size of encapsulation devices down to the scale of individual islet microcapsules increases nutrient diffusion shortly after transplantation compared to macroencapsulation devices, but smaller capsule sizes have also been shown to induce a robust foreign body response and subsequent fibrosis.

    “Interestingly, while decreasing the size of encapsulation devices down to the scale of individual islet microcapsules increases nutrient diffusion shortly after transplantation when compared to macroencapsulation devices, smaller capsule sizes have been shown to also induce a robust foreign body response and subsequent fibrosis.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [103] Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR, Li J, Langan E, Wyckoff J, Loo WS, (2015). Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater 14, 643– 651. 25985456 PMC4477281 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The interconnected hydrophobic channel design greatly enhanced islet survival upon transplantation into diabetic mice and allowed the device to be scaled up to 6.6 mm thick.

    “This design greatly enhanced islet survival upon transplantation into diabetic mice and allowed the device to be scaled up to 6.6 mm thick.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [100] Wang LH, Ernst AU, An D, Datta AK, Epel B, Kotecha M, and Ma M (2021). A bioinspired scaffold for rapid oxygenation of cell encapsulation systems. Nat. Commun 12, 1– 16. 34615868 PMC8494927 source

  • May combine two claims.

    Premisecitation

    The triazole-thiomorpholine dioxide alginate formulation was subsequently shown to prevent fibrosis and facilitate cell survival of allogeneic islets in non-human primates.

    “This formulation was subsequently shown to prevent fibrosis and facilitate cell survival of allogeneic islets in non-human primates.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [105] Bochenek MA, Veiseh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E, Omami M, Doloff JC, Mendoza-Elias J, Nourmohammadzadeh M, (2018). Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng 2, 810– 821. 30873298 PMC6413527 source

      The Methods section identifies Z1-Y15 as a triazole–thiomorpholine dioxide modification. The paper reports viable allogeneic islets in non-human primates and no pericapsular fibrotic overgrowth in six of seven animals after transplantation. That supports reduced fibrosis and islet survival, but not the unqualified claim that the formulation prevented fibrosis. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    These accessory mesenchymal stromal cells reduced infiltration of CD4+ and CD8+ effector T-cells and increased the number of Tregs to induce local immune tolerance.

    “These accessory mesenchymal stromal cells reduced infiltration of CD4+ and CD8+ effector T-cells and increased the number of Tregs to induce local immune tolerance.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [116] Wang X, Wang K, Yu M, Velluto D, Hong X, Wang B, Chiu A, Melero-Martin JM, Tomei AA, and Ma M (2022). Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression. Sci. Adv 8, 1– 17. PMC9307254 35867788 source

  • May combine two claims.

    Premisecitation

    Incorporation of the CSF1R inhibitor GW2580 in its crystallized form within alginate microcapsules allowed for its controlled release over time, resulting in long-term reduction of fibrosis and significant improvements in islet transplantation outcomes in mice, even within the subcutaneous space.

    “The incorporation of the CSF1R inhibitor GW2580 in its crystallized form within alginate microcapsules allowed for its controlled release overtime, resulting in long-term reduction of fibrosis and significant improvements in islet transplantation outcomes in mice, even within the subcutaneous space.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [110] Farah S, Doloff JC, Müller P, Sadraei A, Han HJ, Olafson K, Vyas K, Tam HH, Hollister-Lock J, Kowalski PS, (2019). Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations. Nat. Mater 18, 892– 904. 31235902 PMC7184801 source

  • May combine two claims.

    Premisecitation

    Inflammatory cytokines, hypoxia, and hyperglycemia can all induce an ER stress response in β cells that leads to cell dysfunction and apoptosis.

    “Inflammatory cytokines, hypoxia, and hyperglycemia can all induce an ER stress response in β cells that leads to cell dysfunction and apoptosis.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 source

      The “Causes of ER-stressed β cells” section says that inflammatory cytokines, hypoxia, and high glucose can each induce ER stress. It links chronic high glucose to β-cell dysfunction and death, but says ER stress–mediated death from cytokines is controversial and describes the link between hypoxia-mediated ER stress and apoptosis as a possibility, not an established outcome for all exposed cells. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [128] Chen CW, Guan BJ, Alzahrani MR, Gao Z, Gao L, Bracey S, Wu J, Mbow CA, Jobava R, Haataja L, (2022). Adaptation to chronic ER stress enforces pancreatic β-cell plasticity. Nat. Commun 13, 1– 18. 35941159 PMC9360004 source

      The Introduction says inflammation can elicit severe ER stress in β-cells and that chronic, unresolved stress can produce a maladaptive response. The Discussion also identifies cytokines as a possible source of ER stress, but says the study did not mimic hyperglycemia or cytokine action; our copy does not identify hypoxia as a trigger or show that each named trigger leads to both dysfunction and apoptosis. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [129] Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B, and Mirmira RG (2012). Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 61, 818– 827. 22442300 PMC3314371 source

      The Abstract and Discussion report that proinflammatory cytokines are associated with ER-stress responses in β cells and that ER stress may contribute to impaired insulin secretion. They do not establish hypoxia or hyperglycemia as ER-stress triggers, or show that the resulting ER stress leads to apoptosis. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    SC-islets engineered to secrete IL-2 mutein, IL-10, and TGF-β reversed diabetes and survived for at least 8 weeks in an autoimmune diabetes mouse model.

    “These cells reversed diabetes and survived for at least 8 weeks in an autoimmune diabetes mouse model.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [54] Gerace D, Zhou Q, Kenty JH, Boulanger KR, Li H, Melton DA, Gerace D, Zhou Q, Kenty JH, Veres A, (2023). Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Reports Med. 4, 100879. PMC9873825 36599351 source

  • May combine two claims.

    Premisecitation

    Perturbations in normal metabolism and environmental conditions can induce endoplasmic reticulum (ER) stress and initiate the unfolded protein response (UPR).

    “Perturbations in normal metabolism and environmental conditions can induce endoplasmic reticulum (ER) stress and initiate the unfolded protein response (UPR).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [127] Fonseca SG, Gromada J, and Urano F (2011). Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab 22, 266– 274. 21458293 PMC3130122 source

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    hPSCs with HLA-A, B, and C deleted except HLA-A2, retaining HLA-E, and CIITA removed differentiated into SC-islets that demonstrated protection from T-cell mediated rejection and reduced NK immune responses in allogeneic humanized mice.

    “These hPSCs could differentiate into SC-islets that demonstrated protection from T-cell mediated rejection and reduced NK immune responses in allogeneic humanized mice.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [55] Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, and Hebrok M (2021). Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538. 34407395 PMC12416289 source

      The Introduction and Discussion state that the edited hPSCs differentiated into insulin-producing β-like cells and were protected from T-cell-mediated rejection in a humanized mouse model. The Results report retained HLA-E expression and reduced NK-cell activation, but that response was measured in an in vitro assay, not in the mice; the reduction was observed for a subset of NK cells after IFNγ treatment. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Allografts of isolated mouse islets engineered to transiently display FasL on their surface survived indefinitely if also treated for the first 15 days with rapamycin, whereas those without FasL were rejected within 30 days.

    “Allografts were able to survive indefinitely if also treated for the first 15 days with rapamycin, whereas those without FasL were rejected within 30 days.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [114] Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, and Shirwan H (2011). Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J. Immunol 187, 5901– 5909. 22068235 PMC3232043 source
    • cites [115] Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, and Yolcu ES (2020). Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. Am. J. Transplant 20, 1285– 1295. 31850658 PMC7299172 source

  • May combine two claims.

    Premisecitation

    HLA class I molecules A, B, and C are present on all nucleated cells and present antigens to CD8+ cytotoxic T-cells, while HLA class II proteins activate CD4+ helper T-cells.

    “The HLA class I molecules A, B, and C are present on all nucleated cells and present antigens to CD8+ cytotoxic T-cells, while HLA class II proteins activate CD4+ helper T-cells.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [117] Bluestone JA, and Tang Q (2020). Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes. Cell Stem Cell 27, 505– 507. 33007232 source

      No passage from our copy matched the claim. Searches for HLA, MHC class I, CD8 T cells, and CD4 T cells returned no passages, so the copy does not establish the stated distribution or functions of HLA class I and II molecules. (LLM, conf=0.72)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Alginate microcapsules fabricated to release the immunomodulatory chemokine CXCL12 improved encapsulated SC-islet survival and reduced the fibrotic response in mice.

    “For example, alginate microcapsules fabricated to release the immunomodulatory chemokine CXCL12 improved encapsulated SC-islet survival and reduced the fibrotic response in mice.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [108] Alagpulinsa DA, Cao JJL, Driscoll RK, Sirbulescu RF, Penson MFE, Sremac M, Engquist EN, Brauns TA, Markmann JF, Melton DA, (2019). Alginate-microencapsulation of human stem cell–derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am. J. Transplant 19, 1930– 1940. 30748094 source

  • May combine two claims.

    Premisecitation

    FasL induced local immune tolerance by causing apoptosis in alloreactive T-cells and promoting the development of regulatory T-cells (Tregs) for long-term maintenance.

    “They demonstrated that FasL induced local immune tolerance by causing apoptosis in alloreactive T-cells and as well as promoting the development of regulatory T-cells (Tregs) for long-term maintenance.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [114] Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, and Shirwan H (2011). Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J. Immunol 187, 5901– 5909. 22068235 PMC3232043 source
    • cites [115] Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, and Yolcu ES (2020). Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. Am. J. Transplant 20, 1285– 1295. 31850658 PMC7299172 source

      The Results report that SA-FasL-engineered islets induced death of alloreactive T cells, and the Discussion says Treg cells are required to maintain long-term graft-localized immune privilege. However, the Discussion presents generation of Tregs in the graft milieu as a possibility, not a demonstrated effect of FasL; it also distinguishes systemic tolerance during induction from local immune privilege during maintenance. No page numbers are available in our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    SC-EC cells may be detrimental to SC-β cell potency, but no safety issues have been reported to date.

    “Fortunately, while they may be detrimental to SC-β cell potency,47 no safety issues have been reported to date.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source

  • May combine two claims.

    Premisecitation

    Oxygen generating materials inserted alongside the islet graft improve oxygen levels at the transplantation site, and another strategy directly pumps oxygen into an encapsulation device.

    “To specifically improve oxygen levels at the transplantation site, oxygen generating materials have been inserted alongside the islet graft,96,98,99 while another strategy directly pumps oxygen into an encapsulation device92,97.”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites [96] Pedraza E, Coronel MM, Fraker CA, Ricordi C, and Stabler CL (2012). Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. Proc. Natl. Acad. Sci 109, 4245– 4250. 22371586 PMC3306668 source

      The study reports that oxygen-generating PDMS–calcium peroxide disks improved oxygenation and survival in cultured rat islets and 3D constructs (study summary; Coculture methods). It describes use during transplantation as a prospective application, not a demonstrated improvement at a transplantation site (Discussion). The separate claim about pumping oxygen into a device is attached to other citations, not this paper. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [98] Coronel MM, Liang JP, Li Y, and Stabler CL (2019). Oxygen generating biomaterial improves the function and efficacy of beta cells within a macroencapsulation device. Biomaterials 210, 1– 11. 31029812 PMC6527135 source
    • cites [99] Wang L-H, Ernst AU, Flanders JA, Liu W, Wang X, Datta AK, Epel B, Kotecha M, Papas KK, and Ma M (2021). An inverse-breathing encapsulation system for cell delivery. Sci. Adv 7, 5835– 5849. PMC8121434 33990318 source

  • May combine two claims.

    Premisecitation

    While SC-islets appear to be generally more stress-resistant than isolated primary islets, they nevertheless respond to inflammatory cytokines with similar stress response pathways.

    “Furthermore, while SC-islets appear to be generally more stress-resistant than isolated primary islets,136 they nevertheless respond to inflammatory cytokines with similar stress response pathways,137”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source
    • cites [137] Demine S, Schiavo AA, Marín-Cañas S, Marchetti P, Cnop M, and Eizirik DL (2020). Pro-inflammatory cytokines induce cell death, inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells. Stem Cell Res. Ther 11, 1– 15. 31900242 PMC6942385 source

  • May combine two claims.

    Premisecitation

    For SC-islet transplantations in mice, site and dose influence cure efficacy, with placement underneath the kidney capsule producing much better results than subcutaneous infusions.

    “For SC-islet transplantations, site and dose have been shown to influence cure efficacy in mice, with placement underneath the highly-vascularized kidney capsule producing much better results than subcutaneous infusions.143,150”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [143] Faleo G, Russ HA, Wisel S, Parent AV, Nguyen V, Nair GG, Freise JE, Villanueva KE, Szot GL, Hebrok M, (2017). Mitigating Ischemic Injury of Stem Cell-Derived Insulin-Producing Cells after Transplant. Stem Cell Reports 9, 807– 819. 28803916 PMC5599226 source

      The Results section, “Attrition of SCIPC and Mature Islet Grafts after Transplant” (page unavailable), reports better SCIPC graft survival under the highly vascularized kidney capsule than at a subcutaneous site. But it measured graft survival in non-diabetic mice, not cure efficacy, and does not establish an effect of transplant dose on cure. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [150] Maxwell KG, Kim MH, Gale SE, and Millman JR (2022). Differential function and maturation of human stem cell-derived islets after transplantation. Stem Cells Transl. Med 11, 322– 331. 35294547 PMC8968674 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Large scale (>1,000 L) bioreactors for mammalian cell culture have been used in the biotechnology industry for decades.

    “Large scale (>1,000 L) bioreactors for mammalian cell culture have been used in the biotechnology industry for decades.177”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [177] Nienow AW (2006). Reactor engineering in large scale animal cell culture. Cytotechnology 50, 9– 33. 19003068 PMC3476006 source

  • May combine two claims.

    Premisecitation

    These gene knockdowns decreased T-cell activation and T-cell induced apoptosis when SC-islets were co-cultured with peripheral blood mononuclear cells.

    “Furthermore, these gene knockdowns decreased T-cell activation and T-cell induced apoptosis when SC-islets were co-cultured with peripheral blood mononuclear cells.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source

      The Results section ('Genetic manipulation increases protection of SC-islets from apoptosis mediated by allorecognition in vitro'; page not provided) reports reduced T-cell activation and fewer apoptotic SC-islets after gene knockdown and co-culture with allogeneic T1D PBMCs. It attributes the apoptosis to stress and allorecognition, but does not establish that T cells specifically induced it. (LLM, conf=0.82)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Implanting a device into the subcutaneous space one month prior to cell transplantation pre-vascularized the graft site and avoided the several week lag time for vascularization.

    “For example, implanting a device into the subcutaneous space one month prior to cell transplantation pre-vascularized the graft site and avoided the several week lag time that it takes for vascularization to occur.145,151”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [145] Pepper AR, Gala-Lopez B, Pawlick R, Merani S, Kin T, and Shapiro AMJ (2015). A prevascularized subcutaneous device-less site for islet and cellular transplantation. Nat. Biotechnol 33, 518– 523. 25893782 source
    • cites [151] Pepper AR, Pawlick R, Bruni A, Wink J, Rafiei Y, O’Gorman D, Yan-Do R, Gala-Lopez B, Kin T, MacDonald PE, (2017). Transplantation of human pancreatic endoderm cells reverses diabetes post transplantation in a prevascularized subcutaneous site. Stem Cell Reports 8, 1689– 1700. 28591651 PMC5470173 source

      The Introduction describes temporarily implanting an angiocatheter to create a vascularized subcutaneous site before infusing the cell graft, and Experimental Procedures confirms that vascular catheters were used to prepare the site. Our copy does not specify implantation one month before transplantation or state that this avoided a several-week vascularization lag. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Stress from a high glucose environment can cause downregulation of key islet genes and decreased function in human islets and animal models, implicating that adequate glucose control is important for β cell health in the immediate aftermath of transplantation.

    “Stress from a high glucose environment can cause downregulation of key islet genes and decreased function in human islets135 and animal models123, implicating that adequate glucose control is important for β cell health in the immediate aftermath of transplantation.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [135] Dai C, Kayton NS, Shostak A, Poffenberger G, Cyphert HA, Aramandla R, Thompson C, Papagiannis IG, Emfinger C, Shiota M, (2016). Stress-impaired transcription factor expression and insulin secretion in transplanted human islets. J. Clin. Invest 126, 1857– 1870. 27064285 PMC4855919 source
    • cites [123] Biarnés M, Montolio M, Nacher V, Raurell M, Soler J, and Montanya E (2002). β-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51, 66– 72. 11756324 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Incorporating VEGF-releasing capsules into a pre-vascularization strategy or transplanting islets within VEGF-releasing hydrogels further improved vessel formation.

    “Incorporating vascular endothelial growth factor (VEGF)-releasing capsules into a similar pre-vascularization strategy152 or transplanting islets within VEGF-releasing hydrogels153 were shown to further improve vessel formation.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [152] Kasoju N, Pátíková A, Wawrzynska E, Vojtíţková A, Sedlačík T, Kumorek M, Pop-Georgievski O, Sticová E, Kříž J, and Kubies D (2020). Bioengineering a pre-vascularized pouch for subsequent islet transplantation using VEGF-loaded polylactide capsules. Biomater. Sci 8, 631– 647. 31729495 source
    • cites [153] Weaver JD, Headen DM, Aquart J, Johnson CT, Shea LD, Shirwan H, and García AJ (2017). Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites. Sci. Adv 3. PMC5457148 28630926 source

  • May combine two claims.

    Premisecitation

    SC-islets exhibited dysfunction, apoptosis, and increased expression of stress and immune interaction genes when exposed to a cytokine mix, thapsigargin, and high glucose.

    “Specifically, SC-islets exhibited dysfunction, apoptosis, and increased expression of genes related to stress and immune interaction when exposed to a variety of stressors, including a cytokine mix to mimic inflammatory stress, thapsigargin to induce ER stress, and high glucose to replicate metabolic stress.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source

  • May combine two claims.

    Premisecitation

    Lentiviral shRNA knockdown of XBP1, CDKN1A, NLRC5, and β2M decreased apoptosis in SC-islets treated with stressors and downregulated stress and immune interaction genes.

    “Lentiviral shRNA knockdown of XBP1, CDKN1A, NLRC5, and β2M decreased the level of apoptosis in SC-islets when treated with these stressors as well as downregulated the expression of genes associated with stress responses and immune interaction.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [136] Leite NC, Pelayo GC, and Melton DA (2022). Genetic manipulation of stress pathways can protect stem-cell-derived islets from apoptosis in vitro. Stem Cell Reports 17, 766– 774. 35245439 PMC9023776 source

  • May combine two claims.

    Premisecitation

    PSCs are sensitive to mechanical cues, and changes in shear stress due to increases in reactor volume, impeller speed, and impeller size will require careful optimization.

    “Critically, PSCs are sensitive to mechanical cues,179,180 and changes in shear stress due to increases in reactor volume as well as impeller speed and size will require careful optimization.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [179] Niebruegge S, Bauwens CL, Peerani R, Thavandiran N, Masse S, Sevaptisidis E, Nanthakumar K, Woodhouse K, Husain M, Kumacheva E, (2009). Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol. Bioeng 102, 493– 507. 18767184 source
    • cites [180] Ismadi MZ, Gupta P, Fouras A, Verma P, Jadhav S, Bellare J, and Hourigan K (2014). Flow characterization of a spinner flask for induced pluripotent stem cell culture application. PLoS One 9. PMC4184809 25279733 source

  • Classified as probably not a substantial claim.

    Premisecitation

    In this approach, endocrine cells are single-cell dispersed from the culture surface and aggregated into islet-like clusters in suspension culture.

    “The endocrine cells are then single-cell dispersed from the culture surface and aggregated into islet-like clusters in suspension culture.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [39] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, and Millman JR (2020). Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat. Biotechnol 38, 460– 470. 32094658 PMC7274216 source
    • cites [57] Hogrebe NJ, Maxwell KG, Augsornworawat P, and Millman JR (2021). Generation of insulin-producing pancreatic β cells from multiple human stem cell lines. Nat. Protoc 16, 4109– 4143. 34349281 PMC8529911 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationnone given

    A stem cell-derived product could be genetically engineered to have advantageous features not found in primary islets, such as resistance to hypoxia or ability to evade the host immune system.

    “Furthermore, a stem cell-derived product could also be genetically engineered to have advantageous features not found in primary islets, such as resistance to stressors like hypoxia or being able to evade the host immune system.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisereasoning

    In the Vertex trial, cells were transplanted without an immune-protective device to avoid problems with nutrient exchange and fibrosis, and thus the patients required immunosuppressive drugs to ensure graft survival.

    “Furthermore, these cells were transplanted without an immune-protective device to avoid problems with nutrient exchange and fibrosis, and thus the patients required immunosuppressive drugs to ensure graft survival.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    A cell replacement therapy could provide a functional cure for T1D if β cells secrete insulin properly in response to glucose stimulation and are transplanted in a location that facilitates adequate exchange of glucose and insulin with the blood stream.

    “Rather, as long as the β cells secrete insulin properly in response to glucose stimulation and are transplanted in a location that facilitates adequate exchange of these molecules with the blood stream, such a cell replacement therapy could provide a functional cure for T1D.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationreasoning

    SC-islets could be generated from a single cell source using a standardized process, and the resulting cell product could be well-characterized to allow for more predictable transplant outcomes.

    “These stem cell-derived islets (SC-islets) could be generated from a single cell source using a standardized process, and the resulting cell product could be well-characterized to allow for more predictable transplant outcomes.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    While the primates did not achieve complete insulin independence, the transplanted SC-islets significantly reduced their insulin requirements and greatly improved their glycemic control.

    “While the primates did not achieve complete insulin independence, the transplanted SC-islets significantly reduced their insulin requirements and greatly improved their glycemic control, further illustrating their potential utility as a therapy.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [45] Du Y, Liang Z, Wang S, Sun D, Wang X, Liew SY, Lu S, Wu S, Jiang Y, Wang Y, (2022). Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat. Med 28, 272– 282. 35115708 source
    • cites [46] Luo Z, Zhan J, Wu S, Jiang Y, Lu Z, Wang Z, Yi LS, Zhang Y, Sun W, Fang X, (2023). Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat. Metab 5, 29– 40. 36624157 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    The first two patients in the Vertex trial were given half the anticipated target dose to assess the safety profile of VX-880.

    “The first two patients were given half the anticipated target dose to assess the safety profile of their stem-cell derived product, VX-880.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Replacing β cell mass by transplanting pancreatic islets was relatively safe and effective in treating T1D.

    “Importantly, these remarkable studies demonstrated that the concept of replacing β cell mass by transplanting pancreatic islets was relatively safe and effective in treating T1D.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Positive preliminary results reported in a press release indicated that transplantation of SC-islets improved glycemic control in two T1D patients, though the initial findings have not yet been peer-reviewed.

    “While the initial findings have not yet been peer-reviewed, positive preliminary results reported in a press release have indicated that transplantation of these SC-islets improved glycemic control in these two T1D patients (https://www.businesswire.com/news/home/20220606005424/en/).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites https://www.businesswire.com/news/home/20220606005424/en/

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Premisenone given

    The developmental pathways targeted by this process can be very sensitive to changes in timing and signaling intensity, and thus small signaling changes at specific times can lead to large changes in cell fate selection.

    “The developmental pathways targeted by this process can be very sensitive to changes in timing and signaling intensity, and thus small signaling changes at specific times can lead to large changes in cell fate selection.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationnone given

    For the typical T1D patient able to achieve blood sugar targets with insulin injections as indicated by HbA1c, the potentially severe adverse side effects of life-long immunosuppression may not outweigh the benefits of further improved glycemic control.

    “For the typical T1D patient that is able to achieve their blood sugar targets with insulin injections as indicated by their hemoglobin A1c levels, the potentially severe adverse side effects of life-long immunosuppression may not outweigh the benefits of further improved glycemic control.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Life-long immunosuppression has potentially severe adverse side effects.

  • May combine two claims.

    Premisecitation

    SC-EC cells comprise a significant percentage of the final cell population in SC-islets but do not secrete insulin.

    “Because SC-EC cells comprise a significant percentage of the final cell population in SC-islets but do not secrete insulin, differentiation efficiency and SC-islet insulin secretion on a per cell basis could be greatly improved by diverting these SC-EC cells toward a SC-β cell lineage during either the cell specification or maturation stages.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [47] Veres A, Faust AL, Bushnell HL, Engquist EN, Kenty JH, Harb G, Quinn P, Poh Y, Sintov E, Gürtler M, Charting cellular identity during human in vitro β - cell differentiation. Nature, 368– 373. PMC6903417 31068696 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisereasoning

    Many attempts to improve SC-islet generation consist of iterations with different combinations and timings of soluble factors.

    “Consequently, many attempts to improve SC-islet generation consist of iterations with different combinations and timings of soluble factors.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    A substantial fraction of cells in the latest protocols can be α cells along with some δ cells.

    “A substantial fraction can be α cells along with some δ cells.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisenone given

    The latest generation of protocols are better at generating islet-like clusters consisting of mostly endocrine cells, though not all of these are β cells.

    “The latest generation of protocols are better at generating islet-like clusters consisting of mostly endocrine cells, though not all of these are β cells.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationreasoning

    Conceptually, if insulin secretion per cell is doubled, then potentially only half as many cells are needed to cure a patient.

    “For example, conceptually, if insulin secretion per cell is doubled, then potentially only half as many cells are needed to cure a patient.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Further enhancing SC-islets to better mimic the functionality of primary adult islets would reduce the number of cells required for transplantation and make it easier to manufacture sufficient cell numbers.

    “However, further enhancing SC-islets to better mimic the functionality of primary adult islets would reduce the number of cells required for transplantation and make it easier to manufacture sufficient cell numbers.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    The chromatin accessibilities of primary adult islet cell types were much more restricted than those in SC-islet cell types, where the INS gene remained open in SC-α and SC-δ cells in addition to SC-β cells.

    “Moreover, the chromatin accessibilities of primary adult islet cell types were much more restricted than those in SC-islet cell types, where the INS gene remained open in SC-α and SC-δ cells in addition to SC-β cells.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    There appeared to be SC-β cell subpopulations that expressed TPH1, a known marker of SC-EC cells, and that had increased accessibility of binding sites for LMX1A, a transcription factor associated with the SC-EC cell fate.

    “Specifically, there appeared to be SC-β cell subpopulations that expressed TPH1, a known marker of SC-EC cells, and that had increased accessibility of binding sites for LMX1A, a transcription factor associated with the SC-EC cell fate.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Reducing graft volume facilitates an easier transplantation procedure, reduces nutrient exchange requirements at the transplantation site, and opens alternative transplantation site possibilities.

    “Reducing graft volume facilitates an easier transplantation procedure, reduces nutrient exchange requirements at the transplantation site, and opens alternative transplantation site possibilities.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Reducing the required cell number is significant in terms of both the graft volume that needs to be transplanted and cell production costs.

    “Reducing the required cell number is significant in terms of both the graft volume that needs to be transplanted as well as cell production costs.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Increasing insulin secretion per cell in SC-islets can be achieved through improvements in either SC-β cell maturation or by decreasing the percentage of off-target cell populations.

    “Consequently, increasing insulin secretion per cell in SC-islets can be achieved through improvements in either SC-β cell maturation or by decreasing the percentage of these off-target cell populations.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisenone given

    SC-β cells generated with current directed differentiation protocols are still not quite as functional as primary human islets, and their transcriptional and chromatin landscape remains immature.

    “First, SC-β cells generated with current directed differentiation protocols are still not quite as functional as primary human islets, and their transcriptional and chromatin landscape remains immature.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationnone given

    Avoiding the use of biomaterials altogether eliminates the inherent diffusion barriers of encapsulation systems as well as circumvents the biomaterial-induced fibrotic response.

    “Avoiding the use of biomaterials altogether eliminates the inherent diffusion barriers of encapsulation systems as well as circumvents the biomaterial-induced fibrotic response.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    By only targeting the area directly surrounding the implant, these strategies can increase the efficacy of the desired immune modulation while simultaneously avoiding systemic side-effects.

    “By only targeting the area directly surrounding the implant, these strategies can increase the efficacy of the desired immune modulation while simultaneously avoiding systemic side-effects.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Combining the zwitterionic concept with the triazole modification further improved the ability of alginate microcapsules to resist fibrosis and enhanced their mechanical stability.

    “They then combined this zwitterionic concept with the previously discovered triazole modification to further improve the ability of the alginate microcapsules to resist fibrosis and as well as enhance their mechanical stability.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [107] Liu Q, Chiu A, Wang L, An D, Li W, Chen EY, Zhang Y, Pardo Y, McDonough SP, Liu L, (2020). Developing mechanically robust, triazole-zwitterionic hydrogels to mitigate foreign body response (FBR) for islet encapsulation. Biomaterials 230, 119640. 31791840 source

  • May combine two claims.

    Interpretationcitation

    Extended time in vivo tended to open chromatin regions associated with cell-specific identity and maturation, while in vitro culture methods remained relatively ineffective at promoting the same maturation effect.

    “These findings suggested that extended time in vivo tended to open chromatin regions associated with cell-specific identity and maturation, while in vitro culture methods remained relatively ineffective at promoting the same maturation effect.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [75] Augswornworawat P, Hogrebe NJ, Ishahak M, Marquez E, Maestas M, Schmidt M, Veronese-Paniagua D, Gale S, Miller J, Velazco-Cruz L, (2022). Defining the chromatin and transcriptional landscape of stem cell-derived islets. BioRxiv, 1– 59.

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Advances in islet isolation methodologies, immunotherapies, and transplantation techniques have improved islet transplantation outcomes in recent years, improving 5-year insulin independence rates to 50-80%.

    “Advances in islet isolation methodologies, immunotherapies, and transplantation techniques have improved islet transplantation outcomes in recent years, improving 5-year insulin independence rates to 50-80%.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [23] Verhoeff K, Marfil-Garza BA, and Shapiro AMJ (2021). Update on islet cell transplantation. Curr. Opin. Organ Transplant 26, 397– 404. 34148980 source

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationcitation

    Discovering new ways to further address the acute stressors experienced by islets in the immediate aftermath of transplantation could further reduce the degree of β cell loss and dysfunction that impedes long-term restoration of normoglycemia.

    “Discovering new ways to further address the acute stressors experienced by islets in the immediate aftermath of transplantation could further reduce the degree of β cell loss and dysfunction that impedes long-term restoration of normoglycemia.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [126] Emamaullee JA, and Shapiro AMJ (2007). Factors influencing the loss of β-cell mass in islet transplantation. Cell Transplant. 16, 1– 8. 28880676 source

  • May combine two claims.

    Interpretationreasoning

    Increasing the surface-to-volume ratio and decreasing the distance of cells from the outer surface of the device can facilitate better mass transport to the encapsulated cells.

    “Alternatively, increasing the surface-to-volume ratio and decreasing the distance of cells from the outer surface of the device can facilitate better mass transport to the encapsulated cells.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationnone given

    Alternative transplantation sites require a less invasive procedure and provide easier access to the graft for monitoring and possible removal.

    “These sites require a less invasive procedure for transplantation and provide easier access to the graft so that it can be monitored and possibly removed if problems arise.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Transplantation between the rectus abdominis muscle and rectus sheath promoted robust vascularization by week 12 and allowed for SC-islet maturation.

    “Furthermore, this location promoted robust vascularization by week 12 and promoted an environment that allowed for SC-islet maturation.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [46] Luo Z, Zhan J, Wu S, Jiang Y, Lu Z, Wang Z, Yi LS, Zhang Y, Sun W, Fang X, (2023). Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat. Metab 5, 29– 40. 36624157 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Loss of function of the p53 protein is common in the majority of cancers.

    “Loss of function of the p53 protein is common in the majority of cancers,164”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [164] Muller PAJ, and Vousden KH (2013). P53 mutations in cancer. Nat. Cell Biol 15, 2– 8. 23263379 source

  • May combine two claims.

    Premisenone given

    These cells are able to rapidly cure severely diabetic mice and improve glycemic control in non-human primates.

    “These cells are able to rapidly cure severely diabetic mice and improve glycemic control in non-human primates, and continued progress has allowed the field to narrow in on the critical quality attributes of these cells (Figure 3).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    The air-liquid interface protocol robustly generates functional SC-islets in a lab setting, but this culture system would be difficult to adapt to large-scale manufacturing.

    “While this protocol is able to robustly generate functional SC-islets in a lab setting, this air-liquid interface culture system would be difficult to adapt to large-scale manufacturing.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [37] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O’Dwyer S, Quiskamp N, Mojibian M, Albrecht T, (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol 32, 1121– 1133. 25211370 source

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    Data on the transcriptional and chromatin landscape of SC-islet cell types can guide the next generation of protocols for refining SC-islet production to increase insulin secretion per cell and eliminate off-target cell types.

    “These data on the transcriptional and chromatin landscape of SC-islet cell types can guide the next generation of protocols for refining SC-islet production in an effort to increase insulin secretion per cell and eliminate off-target cell types.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationnone given

    Further genetic engineering approaches to improve SC-islet resistance to stressors immediately after transplantation will likely be key to improving graft viability and reducing the number of cells needed for insulin independence.

    “Finally, further genetic engineering approaches to improve SC-islet resistance to the stressors they experience immediately after transplantation will likely be key to improving graft viability and reducing the number of cells needed for insulin independence.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    Single-cell sequencing technologies have allowed for unprecedented characterization of SC-islets, providing insight into the identity and maturation state of the cells produced with these differentiation protocols.

    “For example, single-cell sequencing technologies have allowed for unprecedented characterization of SC-islets, providing insight into the identity and maturation state of the cells produced with these differentiation protocols.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    These immunoprotective approaches offer the potential for avoiding immunosuppressive drugs altogether, broadening the applicability of this cell therapy.

    “These approaches offer the potential for avoiding immunosuppressive drugs altogether, broadening the applicability of this cell therapy.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    This progenitor population could be well-characterized and facilitate the generation of a master cell bank of high-quality pancreatic progenitors.

    “Furthermore, this population could be well-characterized and facilitate the generation of a master cell bank of high-quality pancreatic progenitors.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    This approach could potentially be scaled up further using cell stacks or hyperflask setups.

    “and it could potentially be scaled up further using cell stacks or hyperflask setups.”
    Quote in the paperNot a substantial claim
90 of 90

  • The paper relies on this without support.

    The number of donor pancreases available for islet isolation is limited.

    “Not only are the number of pancreases available for islet isolation limited, but transplanting cells from multiple genetic backgrounds per patient could exacerbate immune rejection and graft failure.25,26”

  • The paper relies on this without support.

    Many patients with T1D still fail to achieve their target blood glucose goals despite advances in insulin pumps and continuous glucose monitors.

    “Despite these advances, however, many patients still fail to achieve their target goals.”

  • The paper relies on this without support.

    Life-long immunosuppression has potentially severe adverse side effects.

    “the potentially severe adverse side effects of life-long immunosuppression may not outweigh the benefits of further improved glycemic control.”

  • The paper relies on this without support.

    Transplanted SC-islets are targeted by the host immune system as foreign, resulting in graft rejection.

    “As with the transplantation of any allogenic material, transplanted SC-islets are targeted by the host immune system as foreign, resulting in graft rejection.”

  • The paper relies on this without support.

    Type 1 diabetes itself is an autoimmune disease that specifically targets β cells.

    “An additional complication is that T1D itself is an autoimmune disease that specifically targets β cells.”

  • The paper relies on this without support.

    Deleting HLAs from cells causes them to be targeted by cells of the innate immune system, such as natural killer (NK) cells and macrophages.

    “Deleting HLAs from cells, however, causes them to be targeted by cells of the innate immune system, such as natural killer (NK) cells and macrophages.”

  • The paper relies on this without support.

    Due to the high metabolic demands of insulin production and secretion, β cells are particularly susceptible to stress.

    “Due to the high metabolic demands of insulin production and secretion, β cells are particularly susceptible to stress.”

  • The paper relies on this without support.

    Native islets are highly vascularized within the pancreas to receive the proper nutrients and high oxygen supply required for the production and secretion of large amounts of insulin.

    “Native islets are highly vascularized within the pancreas to receive the proper nutrients and high oxygen supply required for the production and secretion of large amounts of insulin.”

  • The authors state this as an assumption.

    The required dose of SC-islets for humans is similar to the dose of human islets from deceased donors.

    “Assuming a similar dose as with human islets from deceased donors,175,176 on the order of 109 cells will be required per patient.”

  • The paper relies on this without support.

    Large-scale bioreactors have not yet been extended to hPSCs.

    “To-date, however, such large scales have not been extended to hPSCs”

  • The paper relies on this without support.

    All well-established protocols require approximately one month of culture to achieve functional SC-islets, with additional time needed for SC-β cell maturation.

    “All well-established protocols require approximately one month of culture to achieve functional SC-islets, with additional time needed for SC-β cell maturation.”
11 of 11

Cites

Flagged first, then by citations

3 of the 191 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Hogrebe, N. J., Ishahak, M., & Millman, J. R.
Affiliations
Washington University in St. Louis (US)
Corresponding author
  • Hogrebe, Nathaniel J.
  • Millman, Jeffrey R.
ORCID
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2023-05
Volume
30
Issue
5
Pages
530-548
ISSN
  • 1875-9777 (ISSN-L)
  • 1934-5909
DOI
10.1016/j.stem.2023.04.002
PMC
PMC10167558
OpenAlex
W4372335371
Semantic Scholar
dfa7e9e8eafe11b7af45e1a20e7af08058d67465
Cited by
210
References
191
Citations by year
2026: 59 · 2025: 75 · 2024: 61 · 2023: 15
FWCI
14.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell stem cell (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
Funders
  • JDRF (3-SRA-2023-1295-S-B, 1-FAC-2023-1316-A-N)
  • Washington University in St Louis
  • NIH (T32DK007120, R01DK127497)
  • Edward Mallinckrodt, Jr. Foundation
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
stem cell-derived islets, type 1 diabetes, human pluripotent stem cells, beta cell differentiation, cell therapy, graft viability, immune rejection, transplantation
MeSH terms
Cell Differentiation, Diabetes Mellitus, Type 1, Humans, Islets of Langerhans, Pluripotent Stem Cells, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-29.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-29.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review